Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial).
Details
Serval ID
serval:BIB_EA7AC9923CB4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial).
Journal
International Journal of Radiation Oncology, Biology, Physics
ISSN
1879-355X (Electronic)
ISSN-L
0360-3016
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
81
Number
5
Pages
1228-1235
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Journal ArticlePublication Status: ppublish
Abstract
PURPOSE: Several accelerated partial breast irradiation (APBI) techniques are described in the literature, and apparently, the three-dimensional (3D)-conformal technique is being used increasingly. Nonetheless, the optimal radiation dose is not yet known. Here, we report feasibility and early toxicities of APBI delivering 40 Gy over 5 days, in a phase II trial.
METHODS AND MATERIALS: From October 2007 to September 2008, 25 patients with pT1N0 cancer received 3D-conformal APBI. The prescribed radiation dose was 40 Gy in 4-Gy fractions given twice daily. This technique used two minitangents and an "en face" electron field. Toxicities were systematically assessed at 1, 2, and 6 months and then once every 6 months.
RESULTS: The planning tumor volume for evaluation (PTV_EVAL) coverage was adequate: the mean dose to the PTV_EVAL was 41.8 Gy (range, 41-42.4 Gy). Mean doses to the ipsilateral lung and heart were 1.6 Gy (range, 1.0-2.3 Gy) and 1.2 Gy (range, 1.0-1.6 Gy), respectively. One and two months after completion of APBI, most patients had no or mild erythema (n=16 patients at 1 month; n=25 patients at 2 months); none of these patients developed moist desquamation. After a median follow-up of 12 months, only 1 patient had a significant moderate field contracture (grade 2). Other reported late toxicities were grade 1.
CONCLUSIONS: 3D-conformal APBI (with two minitangents and an "en face" electron field) using a total dose of 40 Gy in 10 fractions twice daily over 5 days achieved appropriate PTV_EVAL coverage and offered significant sparing of normal tissue. Early tolerance was excellent.
METHODS AND MATERIALS: From October 2007 to September 2008, 25 patients with pT1N0 cancer received 3D-conformal APBI. The prescribed radiation dose was 40 Gy in 4-Gy fractions given twice daily. This technique used two minitangents and an "en face" electron field. Toxicities were systematically assessed at 1, 2, and 6 months and then once every 6 months.
RESULTS: The planning tumor volume for evaluation (PTV_EVAL) coverage was adequate: the mean dose to the PTV_EVAL was 41.8 Gy (range, 41-42.4 Gy). Mean doses to the ipsilateral lung and heart were 1.6 Gy (range, 1.0-2.3 Gy) and 1.2 Gy (range, 1.0-1.6 Gy), respectively. One and two months after completion of APBI, most patients had no or mild erythema (n=16 patients at 1 month; n=25 patients at 2 months); none of these patients developed moist desquamation. After a median follow-up of 12 months, only 1 patient had a significant moderate field contracture (grade 2). Other reported late toxicities were grade 1.
CONCLUSIONS: 3D-conformal APBI (with two minitangents and an "en face" electron field) using a total dose of 40 Gy in 10 fractions twice daily over 5 days achieved appropriate PTV_EVAL coverage and offered significant sparing of normal tissue. Early tolerance was excellent.
Keywords
Aged, Breast Neoplasms/pathology, Breast Neoplasms/radiotherapy, Erythema/pathology, Feasibility Studies, Female, Follow-Up Studies, Heart/radiation effects, Humans, Lung/radiation effects, Middle Aged, Organs at Risk/radiation effects, Prospective Studies, Radiation Injuries/pathology, Radiotherapy Dosage, Radiotherapy, Conformal/adverse effects, Radiotherapy, Conformal/methods, Time Factors, Tumor Burden
Pubmed
Web of science
Create date
01/12/2014 17:07
Last modification date
20/08/2019 16:12